All In Biotech

Free tool

FAERS Monitor: Leukine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 103362 or its brand name (Leukine, Sargramostim). Reports on generic versions are filed under their own applications.

Reports

1,730

Serious

1,272

74% of reports

Hospitalization

581

Death reported

255

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia158
  • off label use155
  • nausea128
  • pain113
  • hypotension111
  • dyspnoea110
  • fatigue94
  • diarrhoea87
  • death84
  • vomiting83
  • dizziness63
  • chills57
  • dehydration57
  • syncope54
  • febrile neutropenia52

Reports by year received

View as table
YearReports
200440
200547
200678
200765
2008167
200958
201068
2011128
2012142
201392
201458
201557
201678
201767
201872
201948
202039
2021107
202276
202362
202445
202568
202666

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,429 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal529.57.3390
hypotensionSignal1116.75.6541
syncopeSignal546.65.0250
chillsSignal575.94.6229
pyrexiaSignal1585.64.8595
dehydrationSignal575.24.0190
dyspnoeaSignal1102.42.087
painSignal1132.21.978
off label useSignal1552.21.999
vomitingSignal832.11.751
nausea1282.01.762
diarrhoea871.61.322
dizziness631.51.212
fatigue941.51.214
death841.21.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.